Mutations of p53 were identified in more than 50% of primary tumors, and heterozygous germline mutations in the p53-encoding gene (TP53) are the cause of Li-Fraumeni syndrome, a disease characterized by increased cancer incidence with a 10% risk to develop osteosarcomas [2]. This evidence concerns the gene TP53 and Li-Fraumeni syndrome.